Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
NEW YORK, Aug. 07, 2017 -- Shepherd, Finkelman, Miller & Shah, LLP (“SFMS”) announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey (Civil Action No. 17-05011) against Ocular Therapeutix, Inc. (“Ocular” or the “Company”) (Nasdaq:OCUL) and certain of its officers and directors. The case seeks remedies under the Securities Exchange Act of 1934 and is brought on behalf of a class consisting of all persons or entities that acquired Ocular securities between May 5, 2017 and July 6, 2017, inclusive (the “Class Period”). If you would like to discuss this action or have any questions regarding this notice or your rights, please contact either Bruce Parke ([email protected]) or Jonathan Dilger ([email protected]); (866) 540-5505.
The Complaint alleges that, throughout the Class Period, Ocular made false and/or misleading statements and/or failed to disclose that: (1) the Company was experiencing issues concerning the manufacture of its lead product, Dextenza, including that more than half the lots the Company produced contained bad product; (2) the foregoing issues could jeopardize Dextenza’s prospects of approval by the FDA; and (3) as a result, defendants’ public statements were materially false and misleading at all relevant times.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN AN ATTORNEY. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS TIME. If you purchased or otherwise acquired Ocular securities during the Class Period, we encourage you to contact us with any questions prior to the September 5, 2017 lead plaintiff motion deadline.
SFMS is recognized as an accomplished firm in the areas of securities, corporate governance, antitrust and employee benefits litigation with offices in California, Connecticut, Florida, New Jersey, New York and Pennsylvania, as well as affiliate offices in London, England, and Milan, Italy. SFMS has recovered hundreds of millions of dollars on behalf of investors. For more information visit us at http://www.sfmslaw.com.
Contacts: Bruce Parke Jonathan Dilger Shepherd Finkelman Miller & Shah, LLP www.sfmslaw.com Telephone: (866) 540-5504 Email: [email protected] [email protected]
